U.S. Trade Distributors Stock News

Solventum (NYSE:SOLV) appointed Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer. Zieselman brings finance leadership experience from prior roles at Surgery Partners Inc. and Stryker Corporation. The appointment places him in a key role overseeing Solventum's accounting and financial reporting functions. Solventum operates in the healthcare sector, where accounting rigor and clear financial reporting are closely watched by investors and regulators. A new...

Equifax stock has fallen about 29% over the past five years, yet the latest Discounted Cash Flow (DCF) estimate suggests the intrinsic value could sit well above where the market is pricing the shares today, while earnings-based multiples look closer to fair. Over five years the share price is down about 29%, which means long-term holders have seen material capital pressure even before considering today’s valuation checks. Recent revenue growth, the planned acquisition in Mexico and expanded...

Firefly Aerospace stock has had a weak month, with the share price under pressure while the market based valuation checks suggest it is not a clear bargain at current levels. The share price is down 28.3% over the past month, which puts recent performance firmly on the back foot for anyone who bought in recently. Future revenue and cash flow expectations can support the current price if they materialise, but any setbacks to execution or funding plans may weigh heavily on how investors value...

Cencora stock has delivered strong long term returns over the past five years, yet the current share price still screens as cheap relative to its intrinsic value estimate and traditional valuation multiples. With both the Discounted Cash Flow (DCF) model and the market based checks pointing in the same direction, investors are weighing how much of Cencora's story is already reflected in the price. Cencora has returned 171.7% over the past five years, which puts the recent valuation signals...

Amneal Pharmaceuticals stock has delivered a very strong 345.7% return over the past 3 years, yet its valuation checks lean more on the expensive side rather than flagging it as a clear bargain. Over the last 3 years Amneal Pharmaceuticals has returned 345.7%, which puts extra focus on whether the current share price already reflects much of the good news. Recent earnings strength and higher expectations for future revenue and profit can support the current valuation, but any disappointment...

In late July 2026, Everforth, Inc. reported second-quarter 2026 results showing sales of US$1,007.0 million and net income of US$14.2 million, issued third-quarter guidance for revenues of US$994.0 million to US$1,024.0 million and net income of US$14.5 million to US$23.0 million, and confirmed diluted EPS guidance of US$0.36 to US$0.56. Alongside softer earnings, Everforth completed a US$77.5 million buyback of 1,796,224 shares, highlighting management’s continued focus on returning capital...

Global markets are being pulled in different directions by inflation questions, shifting rate expectations and uneven growth across regions. In this kind of backdrop, many investors are looking past quarterly headlines and focusing on founders who are deeply invested in the long term. The Top Founder-Led Companies screener targets leaders with significant skin in the game and tight capital discipline. That combination can help align your interests with theirs, regardless of which sector is in...

In late July 2026, Dolby Laboratories reported third‑quarter results showing revenue of US$305 million and net income of US$28.6 million, alongside new fourth‑quarter and full‑year 2026 guidance, a US$0.36 dividend, and an expanded share repurchase authorization to US$3.65 billion. Although quarterly profit eased year on year, Dolby’s decision to raise its buyback capacity and maintain dividends underscores management’s emphasis on returning cash to shareholders while its licensing programs...

In July 2026, Wyndham Hotels & Resorts reported second-quarter revenue of US$375 million, down from US$397 million a year earlier, while net income increased to US$102 million and diluted earnings per share from continuing operations rose to US$1.36 from US$1.13. Alongside higher earnings, the company raised its full-year 2026 net revenue and global RevPAR outlook and continued its multi-year share repurchase program, signaling confidence in its business model and cash generation. Now we’ll...

In July 2026, Xerox Holdings Corporation reported second-quarter results showing revenue of US$1,922 million and net income of US$13 million, alongside a smaller six-month net loss and higher year-to-date revenue versus the prior year. The company also raised its full-year 2026 guidance to approximately US$7.60 billion in revenue and increased synergy targets from its Lexmark collaboration, highlighting progress on priorities to stabilize revenue, improve profitability, and reduce...

Peabody Energy (BTU) has drawn fresh attention after second quarter results on July 29 showed higher sales and a shift to a net loss, along with a dividend affirmation and an update on its ongoing share repurchase program. See our latest analysis for Peabody Energy. The earnings release appears to have cooled short term sentiment around Peabody Energy, with the share price down 6.5% over the past week and 30.5% year to date, although the 1 year total shareholder return of 34.3% and 5 year...

BD (Becton, Dickinson and Company) and EMS previously announced a collaboration to launch a semaglutide therapy in Brazil, using BD’s Vystra Injection Pen platform designed for ease of use in treating chronic conditions such as obesity and type 2 diabetes. This partnership highlights how BD’s drug delivery expertise is being applied to support rising demand for injectable GLP-1 therapies in a major emerging healthcare market. Next, we’ll examine how BD’s role in semaglutide delivery through...

AbbVie stock slipped about 2.5% today and is roughly flat over the past month, even after a strong second quarter that pushed adjusted earnings per share to $3.65 and revenue to nearly $17.0b. The market is reacting to the near term. The numbers are pointing you to a longer story. The headline is simple. AbbVie just delivered double digit revenue growth in a period when investors are still focused on legacy patent risks and a very rich trailing P/E of about 123x. The real question now is how...

Advance Auto Parts stock is coming off a long weak stretch, with a sharply negative five year return, while the current valuation checks still suggest the shares are not a clear bargain. After a solid rebound this year, investors now face a stock that screens as expensive on broad metrics rather than obviously cheap after the pullback. Over the past five years, Advance Auto Parts has delivered a return of about 69.5% in decline, which puts extra focus on whether the recent recovery leaves...

Jabil stock has delivered a very large 5 year return, yet at around US$315 per share the intrinsic value estimate based on a Discounted Cash Flow (DCF) model and the market multiples both still point to the shares screening as undervalued. Jabil has returned 436.5% over the past 5 years, which puts extra focus on whether the current price still offers a margin between market value and intrinsic value. The key support for the current valuation is the market's view of Jabil's ability to keep...

The market loved nVent Electric’s latest quarter. The stock jumped 6.2% to US$153.83, even though it had been flat over the past week and slightly down over the past month and quarter. That is a sentiment reset in a single session. The spark was not a soft beat. nVent Electric delivered record Q2 sales of US$1.471b and adjusted earnings per share of US$1.45, with management lifting full year revenue and earnings guidance. Investors are treating this as confirmation that the data center and...

Surgery Partners (SGRY) recently reaffirmed its 2026 earnings guidance, telling investors to expect revenues between US$3.35b and US$3.45b. This keeps attention on how the company balances this outlook with ongoing operational challenges. See our latest analysis for Surgery Partners. Despite reaffirmed guidance, Surgery Partners’ recent trading tells a mixed story. The stock has fallen about 7% on a 30 day share price return basis but is still up nearly 8% over 90 days. The 1 year total...

Lamar Advertising (LAMR) has drawn fresh attention after recent share price moves, with the stock closing at US$159.96. Investors are weighing this against the company’s size, business mix and recent return profile. See our latest analysis for Lamar Advertising. While Lamar Advertising’s share price eased 0.43% over the last session to US$159.96, the 90 day share price return of 13.97% and one year total shareholder return of 38.95% indicate momentum has been building over both shorter and...

Lincoln Educational Services stock has delivered very strong gains over the past few years, yet investors now face a split valuation picture where the Discounted Cash Flow (DCF) intrinsic value suggests a sizeable discount to current pricing, while earnings-based multiples point to a richer valuation. Lincoln Educational Services has returned very close to 5x over the past 3 years, which puts extra focus on whether recent gains are fully backed by fundamentals. Expectations for the company...

Cooling inflation, falling energy prices in June and a likely squeeze on retirees’ real spending power are reshaping how investors think about steady, everyday spending on essentials. Consumer staples stocks often sit at the center of that conversation, because they sell the products that households keep buying even as Social Security adjustments and Medicare costs shift budgets. This article looks at three Consumer Staples Stocks screener picks that appear positively exposed to the latest...

Organon just posted fresh quarterly numbers and the stock has gone nowhere. The share price sits flat at US$13.55, even as the latest earnings reset the story after a recent quarterly loss. That calm surface hides a real debate. Profitability has been squeezed, with net profit margin over the last year at 4% compared with 11.9% a year earlier, and interest costs are pressing hard on earnings. For you as an investor, the question is simple: Is the market correctly pricing a balance sheet under...

MARA Holdings comes into focus with a weak long term share price record and a low overall value score, even as investors weigh its pivot toward AI data centers and ongoing legal disputes in France. The question for investors is whether the recent share price leaves enough room for a margin of safety after years of falling returns. Over the last 5 years, MARA Holdings stock has declined 66.9%, which signals that long term shareholders have taken on significant capital losses. The push into AI...

Long-term Treasury yields have jumped to levels not seen since before the financial crisis, and the Federal Reserve looks comfortable letting borrowing costs stay higher for longer. That combination tends to put pressure on richly priced growth stocks and draw more attention to companies that already return a lot of cash to shareholders. High projected dividend yields of 4% or more, backed by solid balance sheets and reasonable payout ratios, can look especially interesting when bond markets...

Linde shareholders woke up to a shock. The stock is down almost 6% from the prior close, even though the company just posted record quarterly sales of about US$9.3b and record earnings per share above US$4.40. The headline this quarter is not demand or growth. It is a squeeze in operating margin that clipped sentiment just as expectations around premium industrial gas profits had risen. That tension between record income and softer profitability is what is driving today’s repricing. The rest...